University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Kirsten L. Greene, MD

Kirsten L. Greene, MD

Clinical Instructor, Department of Urology, UCSF

Selected Publications

  1. Lake ST, Greene KL, Westphalen AC, Behr SC, Zagoria R, Small EJ, Carroll PR, Hope TA. Optimal MRI sequences for 68Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer. EJNMMI Res. 2017 Sep 19; 7(1):77.
    View on PubMed
  2. Chang I, Mitsui Y, Kim SK, Sun JS, Jeon HS, Kang JY, Kang NJ, Fukuhara S, Gill A, Shahryari V, Tabatabai ZL, Greene KL, Dahiya R, Shin DM, Tanaka Y. Cytochrome P450 1B1 inhibition suppresses tumorigenicity of prostate cancer via caspase-1 activation. Oncotarget. 2017 Jun 13; 8(24):39087-39100.
    View on PubMed
  3. Hope TA, Aggarwal R, Chee B, Tao D, Greene KL, Cooperberg M, Feng F, Chang A, Ryan CJ, Small EJ, Carroll PR. Impact of Ga-68 PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer. J Nucl Med. 2017 May 18.
    View on PubMed
  4. Bucay N, Bhagirath D, Sekhon K, Yang T, Fukuhara S, Majid S, Shahryari V, Tabatabai Z, Greene KL, Hashimoto Y, Shiina M, Yamamura S, Tanaka Y, Deng G, Dahiya R, Saini S. A novel microRNA regulator of prostate cancer epithelial-mesenchymal transition. Cell Death Differ. 2017 Jul; 24(7):1263-1274.
    View on PubMed
  5. Bucay N, Sekhon K, Majid S, Yamamura S, Shahryari V, Tabatabai ZL, Greene K, Tanaka Y, Dahiya R, Deng G, Saini S. Novel tumor suppressor microRNA at frequently deleted chromosomal region 8p21 regulates epidermal growth factor receptor in prostate cancer. Oncotarget. 2016 Oct 25; 7(43):70388-70403.
    View on PubMed
  6. Nip H, Dar AA, Saini S, Colden M, Varahram S, Chowdhary H, Yamamura S, Mitsui Y, Tanaka Y, Kato T, Hashimoto Y, Shiina M, Kulkarni P, Dasgupta P, Imai-Sumida M, Tabatabai ZL, Greene K, Deng G, Dahiya R, Majid S. Oncogenic microRNA-4534 regulates PTEN pathway in prostate cancer. Oncotarget. 2016 Oct 18; 7(42):68371-68384.
    View on PubMed
  7. Nguyen HG, Punnen S, Cowan JE, Leapman M, Cary C, Welty C, Weinberg V, Cooperberg MR, Meng MV, Greene KL, Garcia M, Carroll PR. A Randomized Study of Intraoperative Autologous Retropubic Urethral Sling on Urinary Control after Robotic Assisted Radical Prostatectomy. J Urol. 2017 Feb; 197(2):369-375.
    View on PubMed
  8. Shahryari V, Nip H, Saini S, Dar AA, Yamamura S, Mitsui Y, Colden M, Bucay N, Tabatabai LZ, Greene K, Deng G, Tanaka Y, Dahiya R, Majid S. Pre-clinical Orthotopic Murine Model of Human Prostate Cancer. J Vis Exp. 2016 Aug 29; (114).
    View on PubMed
  9. Scherr KA, Fagerlin A, Hofer T, Scherer LD, Holmes-Rovner M, Williamson LD, Kahn VC, Montgomery JS, Greene KL, Zhang B, Ubel PA. Physician Recommendations Trump Patient Preferences in Prostate Cancer Treatment Decisions. Med Decis Making. 2017 Jan; 37(1):56-69.
    View on PubMed
  10. Hope TA, Aggarwal RR, Westphalen AC, Cooperberg MR, Greene KL. Targeted PET imaging for prostate-specific membrane antigen in prostate cancer. Future Oncol. 2016 Nov; 12(21):2393-2396.
    View on PubMed
  11. Roberge G, Stortz SK, Frankel WC, Greene KL, Deng DY. Identifying Prevalence and Risk Factors for Mild Cognitive Impairment in Adults Presenting for Urological Evaluation. Urology. 2016 Aug; 94:29-35.
    View on PubMed
  12. Porten SP, Leapman MS, Greene KL. Intravesical chemotherapy in non-muscle-invasive bladder cancer. Indian J Urol. 2015 Oct-Dec; 31(4):297-303.
    View on PubMed
  13. Bucay N, Shahryari V, Majid S, Yamamura S, Mitsui Y, Tabatabai ZL, Greene K, Deng G, Dahiya R, Tanaka Y, Saini S. miRNA Expression Analyses in Prostate Cancer Clinical Tissues. J Vis Exp. 2015 Sep 08; (103).
    View on PubMed
  14. Jalloh M, Leapman MS, Cowan JE, Shinohara K, Greene KL, Roach M, Chang AJ, Chan JM, Simko JP, Carroll PR. Patterns of Local Failure following Radiation Therapy for Prostate Cancer. J Urol. 2015 Oct; 194(4):977-82.
    View on PubMed
  15. Welty CJ, Cowan JE, Nguyen H, Shinohara K, Perez N, Greene KL, Chan JM, Meng MV, Simko JP, Cooperberg MR, Carroll PR. Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer. J Urol. 2015 Mar; 193(3):807-11.
    View on PubMed
  16. Chang I, Fukuhara S, Wong DK, Gill A, Mitsui Y, Majid S, Saini S, Yamamura S, Chiyomaru T, Hirata H, Ueno K, Arora S, Shahryari V, Deng G, Tabatabai ZL, Greene KL, Shin DM, Enokida H, Shiina H, Nonomura N, Dahiya R, Tanaka Y. Cytochrome P450 1B1 polymorphisms and risk of renal cell carcinoma in men. Tumour Biol. 2014 Oct; 35(10):10223-30.
    View on PubMed
  17. Greene KL, Punnen S, Carroll PR. Evolution and immediate future of US screening guidelines. Urol Clin North Am. 2014 May; 41(2):229-35.
    View on PubMed
  18. Sanford MT, Greene KL, Carroll PR. The argument for palliative care in prostate cancer. Transl Androl Urol. 2013 Dec; 2(4):278-80.
    View on PubMed
  19. Starobinets O, Guo R, Simko JP, Kuchinsky K, Kurhanewicz J, Carroll PR, Greene KL, Noworolski SM. Semiautomatic registration of digital histopathology images to in vivo MR images in molded and unmolded prostates. J Magn Reson Imaging. 2014 May; 39(5):1223-9.
    View on PubMed
  20. Majid S, Dar AA, Saini S, Deng G, Chang I, Greene K, Tanaka Y, Dahiya R, Yamamura S. MicroRNA-23b functions as a tumor suppressor by regulating Zeb1 in bladder cancer. PLoS One. 2013; 8(7):e67686.
    View on PubMed

Go to UCSF Profiles, powered by CTSI